Table 1.
Clinical characteristics of the entire European CRT Survey I cohort and the subset of patients used for the external validation of the SEMMELWEIS-CRT score
| The entire European CRT Survey I cohort14 | External validation cohort | |
|---|---|---|
| n = 2438 | n = 1367 | |
| Age, years | 70 (62–76) | 71 (63–77) |
| Male | 73% | 77% |
| Height, cm | Not reported | 170 (165–177) |
| Weight, kg | Not reported | 78 (69–90) |
| BMI, kg/m2 | 26 (24–29) | 26 (24–30) |
| SBP, mmHg | Not reported | 120 (110–135) |
| NYHA functional class | ||
| I | 2% | 2% |
| II | 20% | 20% |
| III | 70% | 69% |
| IV | 8% | 9% |
| Ischemic HF aetiology | 51% | 55% |
| LVEF, % | 27 ± 8 | 27 ± 7 |
| CRT-D | 73% | 75% |
| Previously implanted PPM or ICD | 26% | 26% |
| Hypertension | Not reported | 24% |
| Diabetes | 30% | 30% |
| Atrial fibrillation | 23% | 25% |
| QRS duration, ms | 157 ± 32 | 156 ± 32 |
| LBBB | 68% | 73% |
| Haemoglobin, g/dL | 13.0 (11.7–14.3) | 13.1 (11.8–14.3) |
| Serum sodium, mmol/L | 139 (137–141) | 139 (137–141) |
| Creatinine, µmol/L | 103 (81–133) | 106 (85–136) |
| GFR, mL/min/1.73m2 | Not reported | 56 (42–74) |
| NT-proBNP, pg/mL | 1740 (655–3542) | 2113 (876–4455) |
| ACE-I | 67% | 65% |
| ARB | 24% | 25% |
| Beta-blockers | 84% | 84% |
| Diuretics | 88% | 87% |
| MRA | 46% | 47% |
| Statin | 56% | 56% |
| Antiarrhythmic medication | 24% | 27% |
Continuous variables are presented as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables are reported as percentages to remain consistent with the reporting format of the paper describing the European CRT Survey I dataset.14
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; GFR, glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PPM, permanent pacemaker; SBP, systolic blood pressure.